Lewy Body , CEO of biotech nelotanserin has said the company will focus solely on gene therapies following disappointing results from its Alzheimer’s drug intepirdine and neuroscience offering, Axovant . In 2019 , the company is anticipating phase II results from its AXO-AAV-OPMD , a treatment for Parkinson’s disease, and plans to begin clinical trials for AXO-Lenti-PD , which restores normal muscle function in patients with oculopharyngeal muscular dystrophy.
Pavan Cheruvu, CEO of biotech Axovant has said the company will focus solely on gene therapies following disappointing results from its Alzheimer’s drug intepirdine and neuroscience offering, nelotanserin. In 2019, the company is anticipating phase II results from its AXO-Lenti-PD, a treatment for Parkinson’s disease, and plans to begin clinical trials for AXO-AAV-OPMD, which restores normal muscle function in patients with oculopharyngeal muscular dystrophy.